Novartis Drops Patent Claims Against Ranbaxy

Law360, New York (September 21, 2007, 12:00 AM EDT) -- Pharmaceutical company Novartis International AG has indicated that it is dropping its patent claims against Ranbaxy Laboratories Limited over the top-selling hypertension drug Diovan.

In papers filed in the U.S. District Court for the District of New Jersey, Novartis said that it will dismiss its patent claims against Ranbaxy, because the generic drug maker had amended its abbreviated new drug application with the U.S. Food and Drug Administration, converting its paragraph IV certification to a paragraph III certification.

The effect of this conversion is that Ranbaxy...
To view the full article, register now.